<!doctype html><html lang="en"><head><meta charset="utf-8"> <title>Life after Eroom’s law | Refoundable</title> <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover"> <meta name="description" content="Jack Scannell, who coined Eroom's law, on the end of an era in drug R&amp;D, and the frontiers of drug discovery."> <meta name="theme-color" content="#061E29"> <link rel="alternate" href="/feed.xml" type="application/atom+xml"> <link rel="apple-touch-icon" href="/apple-touch-icon.png"><link rel="icon" href="/favicon.png" type="image/png"><link rel="icon" href="data:image/svg+xml;utf8,%3Csvg%20width%3D'256'%20height%3D'256'%20xmlns%3D'http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg'%3E%3Cg%20fill%3D'none'%20fill-rule%3D'evenodd'%3E%3Cpath%20fill%3D'%23061E29'%20d%3D'M0%200h256v256H0z'%2F%3E%3Cpath%20d%3D'M113.2%20113H87V63.4H136c10.3%200%2020.9.2%2029.9%206a34.8%2034.8%200%200114.8%2029c0%2013.2-7.7%2025.4-20.2%2030l26.9%2065h-30L134%20133.9H73l-15.6-19.1h70.7c5.7%200%2011.9.5%2016.8-2.4%204.5-2.7%206.9-8.2%206.9-13.3%200-4.6-2.8-9.6-6.7-12-4.6-2.9-12.5-2.2-17.6-2.2h-14.4v28zm1%2022.7v44.2H86.8v-44.2H114z'%20fill%3D'%23FFF'%2F%3E%3C%2Fg%3E%3C%2Fsvg%3E" sizes="any" type="image/svg+xml"><link rel="mask-icon" href="/mask-icon.svg" color="#061E29"> <link rel="manifest" href="/manifest.json"> <style>:root{--fontstack-prefix:-apple-system,BlinkMacSystemFont,;--fontstack-sans-serif:"Helvetica Neue",sans-serif;--fontstack-serif:Georgia,serif;--fontstack-monospace:Menlo,Consolas,monospace;--fontstack-default:var(--fontstack-prefix) var(--fontstack-sans-serif);--font-size:1.6vw;--font-features:"halt","ss01","ss02";--line-height:calc(20 / 14);--heading-letter-spacing:-.04em;--breakpoint-lg:1600px;--breakpoint-md:1080px;--breakpoint-sm:640px;--breakpoint-xs:400px;--space-lg:24vw;--space-md:8vw;--space-sm:4vw;--space-xs:1.2vw;--border-lg:4px;--border-md:2px;--border-sm:1px;--link-color:#03549b;--background-color:#fff;--text-color:#000;--code-color:#3914b3;--nav-padding:.75vmax;--nav-item-space:1.4vmax}*,::after,::before{padding:0;margin:0;box-sizing:border-box}html{font-size:100%;-webkit-text-size-adjust:none;-ms-text-size-adjust:none;text-size-adjust:none;text-rendering:optimizelegibility;image-rendering:optimizequality;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;background:var(--bg-color)}body{--space-body:var(--space-lg);padding-top:0;padding-bottom:0;padding-left:var(--space-body);padding-right:var(--space-body);margin:0 auto 0;font-family:var(--fontstack-default);font-size:var(--font-size);font-feature-settings:var(--font-features);line-height:var(--line-height);hanging-punctuation:first allow-end;color:var(--text-color);background:var(--bg-color);-webkit-transition:all .2s ease;transition:all .2s ease}@media (max-width:1080px){body{--space-body:var(--space-md);font-size:calc(var(--font-size) * 1.4)}}@media (max-width:640px){body{--space-body:var(--space-sm);font-size:calc(var(--font-size) * 2.4)}}@media (max-width:400px){body{font-size:calc(var(--font-size) * 3.2)}}input{color:inherit;font-family:inherit;font-size:inherit;line-height:inherit}input{background-image:none}a{color:var(--text-color);text-decoration:none;-webkit-transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease;transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease}a:focus,a:hover{-webkit-transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;text-decoration:underline}hr,img{border:0}::-webkit-input-placeholder{color:var(--text-color);opacity:.2}::-moz-placeholder{color:var(--text-color);opacity:.2}:-ms-input-placeholder{color:var(--text-color);opacity:.2}::-ms-input-placeholder{color:var(--text-color);opacity:.2}:focus::-webkit-input-placeholder{color:var(--link-color)}:focus::-moz-placeholder{color:var(--link-color)}:focus:-ms-input-placeholder{color:var(--link-color)}:focus::-ms-input-placeholder{color:var(--link-color)}.navigation{padding-top:var(--nav-padding);padding-bottom:var(--nav-padding);margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:90%;font-weight:700}.navigation li{display:inline-block;line-height:2}.navigation li a{padding:.5em var(--nav-item-space)}.navigation li a:focus,.navigation li a:hover{color:var(--link-color);text-decoration:none}.content{margin-bottom:16vmin}.content::after,.content::before{display:table;content:""}.content::after{clear:both}.content article>:last-child{margin-bottom:0!important}.content a{font-weight:700}.content a:has(>code){-webkit-text-decoration-color:var(--code-color);text-decoration-color:var(--code-color)}.content p{margin-bottom:1.6rem;line-height:calc(var(--line-height) * 1.2)}.content h2,.content h3{margin:10vmin 0 1rem;font-size:72%;font-weight:400;opacity:.5}.content ol,.content ul{margin-bottom:1.8rem;list-style:none;counter-reset:list}@media (max-width:640px){.content ol,.content ul{margin-left:1em}}.content ol li,.content ul li{line-height:calc(var(--line-height) * 1.2)}.content ol li::before,.content ul li::before{position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none}.content ul li::before{content:"-";padding-right:.5em}.content ol li::before{counter-increment:list;content:counter(list) ".";padding-right:.25em}.content img{--space-deco:var(--space-md);display:block;width:calc(100% + var(--space-deco) * 2);margin-left:calc(var(--space-deco) * -1);margin-right:calc(var(--space-deco) * -1);margin-bottom:1.8rem}@media (max-width:1080px){.content img{--space-deco:var(--space-md)}}@media (max-width:640px){.content img{--space-deco:var(--space-sm)}}.content hr::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.content sup{font-size:75%}.content form input{display:block;width:100%;padding:1vmin 0;margin:0 0 1.8rem;border:none;border-bottom:1px solid var(--text-color);background:inherit;border-radius:0;outline:0;-webkit-transition:padding .2s ease;transition:padding .2s ease}.content form input:focus{border-color:var(--text-color)}.content input:focus:required:invalid:focus{color:var(--link-color);border-color:var(--link-color);box-shadow:none}.footnotes{font-size:80%}.footnotes::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.footer{padding:0 0 16vmin;margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:80%;text-transform:lowercase}.footer ul li{display:inline-block;line-height:1.8}.footer ul li a{padding:.5em var(--nav-item-space)}@media print{*,::after,::before{background:0 0!important;color:#000!important;box-shadow:none!important;text-shadow:none!important}body{padding:10mm!important;margin:0!important;font-size:calc(var(--font-size) * 1.35)}a,a:visited{text-decoration:none}img{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.footer,.navigation{display:none}}:root{--rdmz-h:var(--code-color-h, 253.962264151);--rdmz-s:var(--code-color-s, 79.8994974874%);--rdmz-l:var(--code-color-l, 39.0196078431%)}body,html{max-width:100%;overflow-x:hidden}body{height:100%;width:100%;margin:0}.content{margin-bottom:0}.content h2,.content h3{opacity:1;margin:0}.content ul li::before{content:"\2022"}.content hr::before{margin:0 auto;height:0;width:0}.content a,.navigation,a,figcaption,ol li,p,span,ul li{font-weight:var(--reg-w)}.digest-form-wrapper .head,.digest-form-wrapper .title,.digest-form-wrapper h2,.digest-form-wrapper h3,.essay .head,.essay .rubric,.essay .title,.essay .title a,.essay h2,.essay h2 a,.essay h3{font-weight:var(--sem-w)!important}.essay .cta,.essay .cta a,.essay figure figcaption{font-weight:var(--reg-w)!important}a{color:var(--m-blue)}a:focus::-webkit-input-placeholder{color:var(--m-blue)}a:focus::-moz-placeholder{color:var(--m-blue)}a:focus:-ms-input-placeholder{color:var(--m-blue)}a:focus::-ms-input-placeholder{color:var(--m-blue)}.navigation,a{letter-spacing:var(--txt-ls)}.digest-form-wrapper .title,.digest-form-wrapper h2,.essay .title,.essay .title a,.essay h2{letter-spacing:var(--met-ls)}.digest-form-wrapper .head,.digest-form-wrapper h3,.essay .head,.essay h3{letter-spacing:var(--hed-ls)}.digest-form-wrapper .deck,.digest-form-wrapper p,.essay .cta,.essay .cta a,.essay .deck,.essay ol li,.essay p{letter-spacing:var(--txt-ls)}.essay figure .credits{font-size:95%}.essay .rubric{color:var(--m-accent)}.digest-form-wrapper .title,.essay .title,.essay .title a{color:var(--xm-silver)}.digest-form-wrapper .head,.essay .head{color:var(--x-black)}.essay .cta{color:var(--m-blue)}.digest-form-wrapper p,.essay ol li,.essay p{color:var(--xm-black)}.essay figure figcaption{color:var(--m-gray)}.essay figure .credits{color:var(--x-silver)}.digest-form-wrapper .head,.essay .head{line-height:1}.digest-form-wrapper .deck,.digest-form-wrapper p,.essay .deck,.essay ol li,.essay p{line-height:1.35}.essay .footnotes p{line-height:1.5}.digest-form-wrapper .title,.essay .title{text-decoration:none}.essay .rubric{text-transform:uppercase}.essay ol li{margin-bottom:.3em}.essay hr{padding:0 0 8vw}.bottom-toc,.callout,.essay-nav,.footer,.navigation,figure figcaption{text-align:center}.txt-wrap{white-space:nowrap}.navigation{margin:var(--nil) var(--full-wid);background-color:var(--x-black);padding:0}.navigation li{padding:.5em 0}.navigation li a{color:var(--xx-white)}.navigation li a:focus,.navigation li a:hover{color:var(--xm-silver)!important}.navigation #logomark a svg{width:1.2em;height:1.2em;margin-bottom:-.15rem}.rg-aro{border-right:1px solid;border-bottom:1px solid}.bo-aro{border-right:1.5px solid;border-bottom:1.5px solid}.tp-aro{height:.5em;width:.5em;display:inline-block}.sh-aro{height:.4em;width:.4em;display:inline-block}.blu-aro{color:var(--m-blue)}.slv-aro{color:var(--xxx-silver)}.d-aro{-webkit-transform:rotate(45deg);transform:rotate(45deg)}.r-aro{-webkit-transform:rotate(-45deg);transform:rotate(-45deg)}.u-aro{-webkit-transform:rotate(-135deg);transform:rotate(-135deg)}.ext-aro-bs{position:relative;display:inline-block;vertical-align:middle;color:var(--m-blue);box-sizing:border-box}.ext-aro-bs:after,.ext-aro-bs:before{content:"";box-sizing:border-box}.ext-aro-fo{width:.45em;height:.45em;border-width:1px 1px 0 0;border-style:solid;margin:0 0 1px .3em}.ext-aro-fo:before{right:0;top:-1px;position:absolute;height:1px;box-shadow:inset 0 0 0 32px;-webkit-transform:rotate(-45deg);transform:rotate(-45deg);width:.7em;-webkit-transform-origin:right top;transform-origin:right top}.fn-ext-lnk{margin-left:.15em}.essay-nav{font-size:82%;margin:var(--nil) var(--full-wid) -5vh;padding:0;z-index:1;border-bottom:1px solid var(--x-silver)}.essay-nav ul{margin-bottom:0}.essay-nav ul li{display:inline-block;line-height:2;padding:.5em 0}.essay-nav ul li:before{display:none}.essay-nav a.sticky-btn{font-weight:var(--reg-w);padding:.3em 1em;margin:0 1em;color:var(--l-black);text-decoration:none;-webkit-transition:none;transition:none}.essay-nav a.sticky-btn:hover{opacity:.7}.essay{counter-reset:count-fn 0 count-qst 0;margin:0 auto}.essay .essay-header{padding:8vw 0}.essay .callout .rubric{margin:0 auto -1.5em;position:relative;top:-1.5em}.essay .callout .title{margin:0}.essay .callout .head{margin:0 0 .3em}.essay .callout .deck{margin:0 auto}.essay .callout .byline{display:none}.essay .callout .cta{margin:0;padding-top:.7rem}.essay .callout .cta a{padding-right:.2rem;padding-bottom:.2em;margin-left:1%}.essay .callout .po-aro{margin-bottom:.2em;margin-left:.2em}.essay .section-headings{position:relative;padding-top:8vw!important}.essay .section-headings .title a{text-decoration:none;padding:8vw 0 0}.essay .section-headings .head{max-width:65%}.essay figure figcaption{padding-top:.5rem;margin:auto}.essay figure .credits-blk{display:block}.essay .qst{margin-top:-3em;padding-top:4.2em;font-weight:var(--med-w)}.essay .qst::before{color:var(--m-gray);counter-increment:count-qst;content:counter(count-qst) ".";position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none;padding-right:.25em}.essay .qst-lnk{padding:.2em .3em!important;margin-right:-1.5em}.essay .qst-lnk svg{fill:var(--m-gray);opacity:.4;vertical-align:middle}.essay .fn-btn{background-color:var(--l-silver);position:relative;margin-left:.3em;color:var(--m-gray);font-weight:var(--sem-w);font-size:90%;text-decoration:none}.essay .fn-btn:hover{background-color:var(--xl-silver)}.essay .fn-btn:focus{outline:0}.essay .fn-btn-top{padding:.25em 1em .35em!important;top:.35em;margin-left:.2em}.essay .fn-btn-bot{padding:.35em .8em .3em!important;margin-left:.5em;top:.1em}.essay sup{padding-top:25vh;margin-top:-25vh}.essay .footnotes{font-size:inherit;padding-bottom:2.2vw;border-top:1px solid var(--m-silver);padding-top:2em}.essay .footnotes:before{display:none}.essay .footnotes ol li{display:-webkit-box;display:flex}.essay .footnotes ol li:before{color:var(--m-gray);position:relative;display:inline-block;counter-increment:count-fn;content:counter(count-fn) "."}.bottom-toc{padding-top:2em;border-top:1px solid var(--m-silver);max-width:91%;margin-left:5%}.bottom-toc .po-aro{margin-bottom:.1em;margin-left:.2em}.digest-form-wrapper{margin:8vw auto}.digest-form-wrapper .digest-form-header{margin-bottom:12vw;text-align:center}.digest-form-wrapper .digest-form-header .title{margin-bottom:0}.digest-form-wrapper .digest-form-header .head{margin-bottom:.3em}#mc_embed_signup{max-width:70%;margin:-8vw auto 0;font-size:120%!important;font-weight:400!important;letter-spacing:var(--txt-ls)}#mc_embed_signup form{padding:0!important}#mc_embed_signup .mc-field-group{padding-bottom:0!important}#mc_embed_signup .mc-field-group label{font-size:110%;color:var(--m-gray);margin-bottom:.3em!important}#mc_embed_signup .mc-field-group input{display:block;width:100%;padding:1vmin 0;margin:.3em 0 1.8rem;border:none;border-bottom:1px solid var(--xm-silver);border-radius:0;outline:0;-webkit-transition:padding .2s ease;transition:padding .2s ease}#mc_embed_signup .mc-field-group input:focus::-webkit-input-placeholder{color:var(--text-color)!important}#mc_embed_signup .mc-field-group input:focus::-moz-placeholder{color:var(--text-color)!important}#mc_embed_signup .mc-field-group input:focus:-ms-input-placeholder{color:var(--text-color)!important}#mc_embed_signup .mc-field-group input:focus::-ms-input-placeholder{color:var(--text-color)!important}#mc_embed_signup .mc-field-group input:focus{border-bottom:2px solid var(--xm-black)}#mc_embed_signup .clear{text-align:center}#mc_embed_signup .button{text-align:left;background-color:transparent!important;padding:0!important;margin:0!important;border:none!important;vertical-align:baseline!important;color:var(--m-blue)!important;letter-spacing:var(--txt-ls);display:inline-block;width:initial}#mc_embed_signup .button:hover{text-decoration:underline}#mc_embed_signup .po-aro{position:relative!important;top:-.1em;left:.2em}#mc_embed_signup div#mce-responses{margin:0!important;padding:0!important}#mc_embed_signup div.response{padding:0 0 .6em 0!important;margin:0;width:100%;font-weight:400!important;font-size:90%!important;color:var(--l-black)!important;text-align:center}#mc_embed_signup div.response a{color:var(--m-blue)!important;display:block}#mc_embed_signup #mce-success-response{color:#0b701b!important}#mc_embed_signup div.mce_inline_error{display:none!important}.footer a,.footer p{margin:0 .2em;padding:0 .1em!important}.footer a,.footer p,.footer ul{display:inline-block;text-transform:capitalize}.footer ul li:before{content:" "!important;display:none}.footer .return-top{text-align:center;margin-bottom:6vh}.footer .return-top a{font-size:130%;text-decoration:none;padding:.15em .85em .25em!important;border-radius:7px;margin-left:.2em}.footer .return-top a:hover{text-decoration:none}.footer-light{padding:0;margin:4vh auto 3vh}.footer-light a,.footer-light p{color:var(--xxx-silver)}.footer-light .return-top a{background-color:var(--l-silver)}.footer-light .return-top a:hover{background-color:var(--xl-silver)}:root{--reg-w:400;--med-w:500;--sem-w:600;--hed-ls:-.065em;--met-ls:-.04em;--txt-ls:-.025em;--lg-rubric:70%;--lg-title:210%;--lg-head:395%;--lg-deck:140%;--lg-cta:130%;--lg-bghead:440%;--lg-subhead:160%;--lg-bgcta:150%;--md-rubric:80%;--md-title:240%;--md-head:450%;--md-deck:160%;--md-cta:150%;--md-bghead:450%;--md-subhead:180%;--md-bgcta:170%;--sm-rubric:90%;--sm-title:230%;--sm-head:370%;--sm-deck:180%;--sm-cta:170%;--sm-bghead:430%;--sm-subhead:200%;--sm-bgcta:180%;--xs-rubric:65%;--xs-title:170%;--xs-head:280%;--xs-deck:130%;--xs-cta:130%;--xs-bghead:330%;--xs-subhead:155%;--xs-bgcta:140%;--lg-nav:90%;--md-nav:120%;--sm-nav:140%;--xs-nav:110%;--lg-txt:130%;--md-txt:150%;--sm-txt:170%;--xs-txt:130%;--lg-fn:100%;--mo-fn:80%;--lg-fig:90%;--md-fig:115%;--sm-fig:130%;--xs-fig:95%;--lg-not:110%;--md-not:140%;--sm-not:160%;--xs-not:120%;--lg-foo:80%;--md-foo:105%;--sm-foo:120%;--xs-foo:90%;--xx-black:#0d0d0d;--x-black:#111;--xm-black:#222;--m-black:#272727;--l-black:#333;--xl-black:#444;--m-gray:#555;--m-blue:#03549b;--xx-white:#fff;--xxx-silver:#898989;--xx-silver:#aaa;--x-silver:#bbb;--bf-silver:#bfbfbf;--xm-silver:#cfcfcf;--m-silver:#ddd;--l-silver:#eee;--xl-silver:#e7e7e7;--m-accent:#805e03;--vl-accent:#f6f6f6;--nil:0;--full-wid:-50%;--space-lg:21vw}@font-face{font-family:Barlow;font-style:normal;font-weight:400;src:local("Barlow Regular"),local("Barlow-Regular"),url(https://fonts.gstatic.com/s/barlow/v4/7cHpv4kjgoGqM7E_DMs5ynghnQ.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:Barlow;font-style:italic;font-weight:400;src:local("Barlow Italic"),local("Barlow-Italic"),url(https://fonts.gstatic.com/s/barlow/v4/7cHrv4kjgoGqM7E_Cfs7wH8Dnzcj.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:500;src:local("Barlow Medium"),local("Barlow-Medium"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E3_-gs51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:600;src:local("Barlow SemiBold"),local("Barlow-SemiBold"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E30-8s51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:system-ui;font-style:normal;font-weight:400;src:local(".SFNSText-Regular"),local(".HelveticaNeueDeskInterface-Regular"),local(".LucidaGrandeUI"),local("Segoe UI"),local("Ubuntu"),local("Roboto-Regular"),local("DroidSans"),local("Tahoma")}@font-face{font-family:system-ui;font-style:normal;font-weight:600;src:local(".SFNSText-Medium"),local(".HelveticaNeueDeskInterface-MediumP4"),local(".LucidaGrandeUI"),local("Segoe UI Semibold"),local("Ubuntu Medium"),local("Roboto-Medium"),local("DroidSans-Bold"),local("Tahoma Bold")}:root{--font-size:1.3vw;--fontstack-prefix:'Barlow','Barlow-Local',system-ui;--fontstack-sans-serif:'Barlow','Barlow-Local',system-ui,sans-serif}html{font-family:Barlow,Barlow-Local,system-ui,sans-serif}@media screen and (max-width:799px){.navigation li{padding:.6em .3em;margin:0 .5em 0 0}.essay-nav{display:none}.essay{max-width:100%}.essay p{max-width:94%;line-height:1.4}.essay ol,.essay p{margin-left:3%;margin-bottom:1.2em}.essay ol{max-width:97%;margin-left:0!important}.essay ol li{margin-left:1.5em;line-height:1.4}.essay .callout{margin:0 auto 6vw!important;padding:15% 0 20%}.essay .section-headings{margin-bottom:8vw;left:3%;max-width:100%}.essay figure{margin:11% auto 10%}.essay figure img{width:110%;margin-bottom:0}.essay figure figcaption{max-width:95%}.essay .qst{margin-top:-1.3em;padding-top:2em}.essay .qst::before{margin-left:0;margin-right:.6em;font-weight:var(--sem-w);width:1em;-webkit-box-pack:center;justify-content:center;text-align:center;padding-right:0;position:unset;display:inline-block}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin-top:10vw}.essay .footnotes ol li::before,.essay .footnotes p{font-size:var(--mo-fn)}.essay .footnotes p{margin-left:0;max-width:90%}.essay .footnotes ol li{margin-left:0;padding-top:11vh;margin-top:-11vh}.essay .footnotes ol li:before{margin-top:.05em;margin-left:-2.3em}.essay #deck-eroom{max-width:80%}.bottom-toc{max-width:100%;margin-left:0}.footer ul{margin-left:0}.digest-form-wrapper .digest-form-header{margin-bottom:34vw}#mc_embed_signup{max-width:90%;margin:-20vw auto 0;font-size:150%!important}#mc_embed_signup div.response{width:80%;margin:0 auto}}@media screen and (max-width:400px){.navigation{font-size:var(--xs-nav)}.essay .rubric{font-size:var(--xs-rubric)}.digest-form-wrapper .title,.digest-form-wrapper h2,.essay .title,.essay h2{font-size:var(--xs-title)!important}.digest-form-wrapper .head,.digest-form-wrapper h3,.essay .head,.essay h3{font-size:var(--xs-head)}.digest-form-wrapper .deck,.essay .deck{font-size:var(--xs-deck)}.essay .cta{font-size:var(--xs-cta)}.essay ol li,.essay p{font-size:var(--xs-txt)}.essay figure{font-size:var(--xs-fig)}.bottom-toc a{font-size:var(--xs-cta)}.footer{font-size:var(--xs-foo)}.digest-form-wrapper{margin:16vw auto}.digest-form-header .deck{max-width:55%;margin:0 auto;line-height:1.2}#mc_embed_signup{font-size:120%!important}}@media screen and (min-width:401px) and (max-width:639px){.navigation{font-size:var(--sm-nav)}.essay .rubric{font-size:var(--sm-rubric)}.digest-form-wrapper .title,.digest-form-wrapper h2,.essay .title,.essay h2{font-size:var(--sm-title)!important}.digest-form-wrapper .head,.digest-form-wrapper h3,.essay .head,.essay h3{font-size:var(--sm-head)!important}.digest-form-wrapper .deck,.essay .deck{font-size:var(--sm-deck)!important}.essay .cta{font-size:var(--sm-cta)}.tp-aro{height:.6em;width:.6em}.essay ol li,.essay p{font-size:var(--sm-txt)}.essay figure{font-size:var(--sm-fig)}.bottom-toc a{font-size:var(--sm-cta)}.footer{font-size:var(--sm-foo)}.digest-form-wrapper{margin:16vw auto}.digest-form-header .deck{max-width:55%;margin:0 auto;line-height:1.2}#mc_embed_signup .button{font-size:110%!important}}@media screen and (min-width:640px) and (max-width:799px){.navigation{font-size:var(--md-nav)}.essay .rubric{font-size:var(--md-rubric)}.digest-form-wrapper .title,.digest-form-wrapper h2,.essay .title,.essay h2{font-size:var(--md-title)!important}.digest-form-wrapper .head,.digest-form-wrapper h3,.essay .head,.essay h3{font-size:var(--md-head)}.digest-form-wrapper .deck,.essay .deck{font-size:var(--md-deck)!important}.essay .cta{font-size:var(--md-cta)}.essay ol li,.essay p{font-size:var(--md-txt);margin-left:0}.essay figure{font-size:var(--md-fig)}.bottom-toc a{font-size:var(--md-cta)}.footer{font-size:var(--md-foo)}.tp-aro{height:.55em;width:.55em}.bottom-toc .po-aro{margin-bottom:.15em}.navigation li{margin:0 2em 0}.essay{max-width:95%}.essay ol li{margin-left:0}.essay p{max-width:100%}.essay .section-headings{margin-bottom:6vw;left:0}.essay figure img{width:100%;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:80%}.essay .qst::before{margin-top:0;margin-left:-4em;font-size:100%;font-weight:var(--reg-w);background-color:transparent;width:4em;-webkit-box-pack:end;justify-content:flex-end;text-align:right;padding-right:.25em;position:absolute;display:-webkit-box;display:flex}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin:10vw auto 0 -1.75em;max-width:100%}.essay .footnotes ol,.essay .footnotes p{max-width:100%;width:100%}.essay .footnotes ol li:before{margin-left:0;width:1.5em}.essay #deck-eroom{max-width:66%}.digest-form-wrapper{margin:12vw auto}.digest-form-wrapper .digest-form-header{margin-bottom:26vw}#mc_embed_signup{max-width:70%}#mc_embed_signup div.response{width:100%;margin:0}#mc_embed_signup .po-aro{top:-.05em}}@media screen and (min-width:800px){.navigation{font-size:var(--lg-nav)}.essay .rubric{font-size:var(--lg-rubric)}.digest-form-wrapper .title,.digest-form-wrapper h2,.essay .title,.essay h2{font-size:var(--lg-title)!important}.digest-form-wrapper .head,.digest-form-wrapper h3,.essay .head,.essay h3{font-size:var(--lg-head)}.digest-form-wrapper .deck,.essay .deck{font-size:var(--lg-deck)!important}.essay .cta{font-size:var(--lg-cta)}.essay ol li,.essay p{font-size:var(--lg-txt)}.essay figure{font-size:var(--lg-fig)}.essay .footnotes ol li,.essay .footnotes p{font-size:var(--lg-fn)}.bottom-toc a{font-size:var(--lg-cta)}.footer{font-size:var(--lg-foo)}.navigation li{padding:.5em 0}.navigation li a{padding:.3em 1em;margin:0 2.5em}.essay-nav{display:none}.essay{max-width:95%}.essay ol li,.essay p{max-width:86%;margin-left:5%}.essay .callout{margin:0 auto!important;padding:4% 0 10%}.essay .section-headings{margin-bottom:5vw;left:-1.5em}.essay figure{margin:10% auto 9%}.essay figure img{width:100%;max-width:1200px;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:65%}.essay .fn-btn{border-radius:7px}.essay .footnotes{max-width:100%;margin:8vw auto 0 .9em}.essay .footnotes ol li{padding-top:10vh;margin-top:-10vh;max-width:100%;margin-left:0}.essay .footnotes ol li p{margin-left:0}.essay .footnotes ol li:before{margin-left:-2.75em}.essay #deck-eroom{max-width:58%}}@media screen and (min-width:1080px){.essay-nav{display:block}.essay-nav-scroll{position:fixed!important;width:100%!important;top:0;left:50%;-webkit-transition:background-color .5s cubic-bezier(.28,.11,.32,1);transition:background-color .5s cubic-bezier(.28,.11,.32,1);border-bottom-color:var(--xl-black)!important;background-color:var(--l-black)!important}.essay-btn-scroll{color:var(--xl-silver)!important}.essay{max-width:93%}.essay ol li,.essay p{max-width:91%}.essay figure figcaption{max-width:70%}.essay #deck-eroom{max-width:61%}}</style> <link href="https://fonts.googleapis.com/css?family=Barlow:400,400i,500,600&amp;display=swap" rel="stylesheet"> <link rel="canonical" href="https://refoundable.com/scannellnew"> <meta property="og:type" content="article"> <meta property="og:site_name" content="Refoundable"> <meta property="og:title" content="Life after Eroom’s law"> <meta property="og:url" content="https://refoundable.com/scannellnew"> <meta property="og:description" content="Jack Scannell, who coined Eroom's law, on the end of an era in drug R&amp;D, and the frontiers of drug discovery."> <meta property="og:image" content="https://refoundable.com/assets/img/og-eroom.png"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@refoundable"> </head><body><nav id="top" class="navigation"> <ul> <li id="logomark"> <a href="/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 200"><path d="M85.7 76H45.2V0h75.6c16 0 32.2.3 46.1 9.1a53.5 53.5 0 0122.8 44.7 48.4 48.4 0 01-31.2 46.1L200 200h-46l-36.3-91.7H24L0 78.8h108.9c8.7 0 18.1.8 25.8-3.7a24.2 24.2 0 0010.5-20.5c0-7-4.2-14.7-10.3-18.3-7-4.5-19.2-3.4-27-3.4H85.6v43zm1.4 35v68.1h-42v-68h42z" fill="#FFF" fill-rule="evenodd"></path></svg></a> </li> <li> <a href="/mission">Mission</a> </li> <li> <a href="/soon">Research</a> </li> <li> <a href="/about">About</a> </li> </ul> </nav> <main class="content" role="main"> <script>window.onscroll=function(){window.addEventListener("scroll",stickyNav)}</script> <nav id="sticky-nav" class="essay-nav"> <ul> <li><a class="sticky-btn" href="#s1">Introduction</a></li> <li><a class="sticky-btn" href="#s2">Diagnosis</a></li> <li><a class="sticky-btn" href="#s3">Decline</a></li> <li><a class="sticky-btn" href="#s4">Discovery</a></li> </ul> </nav> <article class="essay"> <div class="essay-header"> <div class="callout"> <div class="meta"> <div class="rubric">Interview&nbsp;&nbsp;•&nbsp;&nbsp;March XX, 2020</div> <div class="title">Secrets</div> </div> <h1 class="head">Life after<br>Eroom’s law.</h1> <p class="deck" id="deck-eroom">Jack Scannell, who coined Eroom's law, on the end of an era in drug R&amp;D, and the frontiers of drug discovery.</p> <div class="byline"> <span>By John Strider</span><span>&nbsp;|&nbsp;</span> <span>Refoundable</span> </div> <div class="cta"><a href="#s1">Introduction</a><div class="rg-aro sh-aro blu-aro po-aro d-aro"></div></div> </div> </div>  <div class="section-headings"> <h2 class="title"><a id="s1">Introduction</a></h2> <h3 class="head">Looking past<br>the end.</h3> </div> <p>One of the founding propositions of Refoundable is that far too many people today make the rational choice to look for secrets in the easy areas that have seen the most progress over the last half-century.</p> <p>A counterintuitive approach at this point may well be to start with the technology areas worst hit by neglect, stagnation and rising costs, and figure out how to restart their <span class="txt-wrap">progress.<sup><a href="#fn1" id="r1" class="fn-btn fn-btn-top">1</a></sup></span></p> <p>Take healthcare for example. While computers got faster and cheaper every year for the last five decades, healthcare costs rose up to four times faster than general inflation in the last two decades <span class="txt-wrap">alone.<sup><a href="#fn2" id="r2" class="fn-btn fn-btn-top">2</a></sup></span></p> <p>Yet, unlike other stagnating technology areas like defense or nuclear energy, we can get most people to agree that healthcare is both deeply broken and crucial to fix, so on the whole, by starting there, less people might try to stop us.</p> <p>Still, a full frontal attack on the healthcare question is ill-advised, as the sheer scale of the field amplifies its inertia, so we’ll apply a lesson from the startup world and focus on breaking through in one key area.</p> <p>Our ideal target would be a field where the more progress we make, the less effort we’d have to put in to discover new secrets. There was a time when people thought about pharmaceutical drugs in those terms.</p> <p>If you could unlock the secrets of biochemistry, the promise was that you’d be able to create all sorts of life-enhancing concoctions, from five-course-meals in a pill to the elixir of eternal youth.</p> <p>Instead, the pharma industry today looks, if anything, like it’s moving in the wrong way. Every day seems to bring even less knowledge on how biological systems work, and the cures seem to get only harder to find, so one might reasonably ask: what went wrong?</p> <p>At first glance, it’s hard to know exactly what’s going on, as the industry puts out an overwhelming torrent of data to tell any bullish or bearish story you like. Fortunately for us, however, the field does have one robust measure of progress that can cut the hype cycle short.</p> <p>It’s called Eroom’s law, and the name is already saying a lot. It’s literally an ironic backward spelling of Moore’s law, the benchmark of progress in the computer industry, so it seems like a fitting place to start.</p> <p style="font-weight:500">Race to the bottom</p> <p>Eroom’s law is the observation that the cost of developing a new drug roughly doubled every nine years from 1950 through the 2010. All in all, it shows a roughly 80-fold decline in the productivity of drug R&amp;D.</p> <p>It’s hard to say what’s worse, the staggering decline or the fact that it went on unchecked for six decades. Either way, as the sum total of our efforts to look for life-saving secrets, Eroom’s law leaves no doubt that our ability to explore the frontier has atrophied catastrophically.</p> <figure> <img class="ful-img" alt="Eroom's law shows the staggering decline in drug R&amp;D productivity" id="img-eroom-1" src="/assets/img/buf.png" data-echo="/assets/img/eroom-1.png"> <figcaption id="cap-eroom-1">By 2010, 9 out of every 10 new drugs never made it to market, while a successful drug cost ten times more to develop than it did in 1960.<span class="credits credits-blk">Jack Scannell</span></figcaption> </figure> <p>Although some aspects of this trendline were known since the 1980s, Eroom’s law was formally articulated only in 2012, in a seminal paper published in <em>Nature</em> by four co-authors led by Jack Scannell.<sup><a href="#fn3" id="r3" class="fn-btn fn-btn-top">3</a></sup></p> <p>In a field plagued by narrow specialization, Jack Scannell is something of a renaissance man, having seen the industry from a distance and up close while working in drug research, private consulting, pharma and biotech investing, and policy advising.</p> <p>When Scannell used to ask the top executives at major pharma firms why their drug R&amp;D productivity was so low, they would repeatedly say it was due to the exhaustion of easy targets, all while deploying billions of dollars in R&amp;D each year.</p> <p>Yet, Scannell believes the problem isn’t that we’re running out of easy pickings, but that our search methods are too often inadequate to find good drug candidates. In effect, we’re very efficiently looking in all the wrong places at great expense, and predictably turning up nothing.<sup><a href="#fn4" id="r4" class="fn-btn fn-btn-top">4</a></sup></p> <p>However, instead of changing its methods, so far the industry has found it easier to pursue commercial opportunities for which existing methods are well-suited. Over the last decade, that’s been pushing pharma companies away from broad therapy areas that affect the wider population, and into narrow therapy areas with small patient groups, like oncology and rare diseases.</p> <p>On the upside, this shift has led to a real uptick since 2010 in drug R&amp;D productivity, suggesting that Eroom’s law bottomed out, though some tough questions remain: Will this uptick continue to hold in the years and decades ahead? And, more to the point, can the industry find its way back to general progress?</p> <p>We sit down with Jack Scannell to assess the record of Eroom’s law at the end of an area, and discuss the future of drug discovery.</p> <div class="footnotes"> <ol> <li id="fn1"> <p>A fair question to ask is: What constitutes a technology field? Taking as a start a simple definition of technology as doing more with less, we believe that any field where some R&amp;D effort is undertaken to improve productivity counts as a technology sector. One surprising result of this definition is that Education, which accounts for over 5 percent of U.S. GDP spending at this point, would hardly qualify as a technology field, since so little of that spending goes to R&amp;D efforts to raise its productivity.<a href="#r1" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn2"> <p><a class="fn-ext-lnk" target="_blank" href=""></a><em>Chart of the day…or century?</em>, American Enterprise Institute, 2019 <a class="fn-ext-lnk" target="_blank" href="https://www.aei.org/carpe-diem/chart-of-the-day-or-century/">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r2" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn3"> <p><em>Diagnosing the decline in pharmaceutical R&amp;D efficiency</em>, Jack Scannell, Alex Blanckley, Helen Boldon, and Brian Warrington, Nature Reviews Drug Discovery, 2012 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1038/nrd3681">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r3" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn4"> <p>Is drug discovery really similar to mining an exhaustible resource, as the drug industry claims? Scannell notes in his work that the real cost of extracting a barrel of oil, or a ton coal or most base metals, has gotten cheaper over time, while the cost of developing a new drug has ballooned exponentially. As a result, Pharma would be in far worse shape if its claim turns out to be true.<a href="#r4" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2 class="title"><a id="s2">Diagnosis</a></h2> <h3 class="head">Opposites<br>attract.</h3> </div> <p class="qst" id="q1">Your 2012 paper perfectly captured the decline that had taken place in drug R&amp;D over the previous six decades. What moved you to write it? And why Eroom’s law?<a class="qst-lnk" href="#q1"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>There was this nagging puzzle: Since the 1950s, lots of important R&amp;D inputs had got tens, hundreds, even billions of times cheaper, while the number of drugs approved per $1 billion spent on R&amp;D had fallen by roughly two orders of magnitude. That struck me as an ugly contrast.</p> <p>Many people bemoaned the R&amp;D productivity problem before, but not enough people had drawn attention to the contrast between input and output efficiency. I thought it was an important public policy problem, and it seemed to attract less attention than it deserved.</p> <p>I remember talking about the contrast with a friend of mine, William Baines. We chatted that drug industry productivity looked like Moore’s law backwards, and that’s how the term “Eroom’s law” was born.</p> <p class="qst" id="q2">The drug industry already knew it had an R&amp;D productivity problem. What was missing from previous attempts to diagnose the problem?<a class="qst-lnk" href="#q2"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lots of the purported diagnoses were not really diagnoses. They were attempts to sell “solutions” that, in many cases, were largely unrelated to the core problems.</p> <p>If, for example, you were an academic geneticist, the productivity problem was an opportunity to promote investment in genomics. If you were an investment bank, big pharma’s low productivity was an opportunity to promote M&amp;A. If you were a consulting firm, you might say that the reporting lines, or the business processes were wrong; things that could be fixed with a re-engineering project.</p> <p>I was working as an investment analyst. A bad prognosis can be very interesting to an analyst, because if you think an industry is in real trouble, you don’t have to own it. That meant I had a different set of biases to most people. And I didn’t have any particular solution to sell.</p> <p>We did reference some very good prior work on the problem. Back in the 1980s, for example, there was a great paper on the R&amp;D slowdown by Fred Steward and George <span class="txt-wrap">Wibberley.<sup><a href="#fn5" id="r5" class="fn-btn fn-btn-top">5</a></sup></span></p> <p>I think lots of people would’ve been better qualified to write the paper, but their day jobs meant they couldn’t write it.</p> <p class="qst" id="q3">Eroom's law was widely adopted after your paper came out. What was the general reaction you saw after you published?<a class="qst-lnk" href="#q3"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>People were certainly glad that someone had put names to things that they knew, or suspected, were happening already. Apart from Eroom’s law itself, people liked something else we talked about in the paper, which I called the “Better than the Beatles Problem.”</p> <p>Imagine how hard it would be to sell new pop songs if every new song had to be better than the Beatles, if you could download all the old Beatles records for free, and if no one ever got bored of listening to the same Beatles’ songs over and over again.</p> <p>That’s analogous to the problem the drug industry faces. Some old drugs are very good. They cost next to nothing when their patents expire. And doctors don’t get bored of prescribing them.</p> <p>So in many therapy areas, you have this ever-expanding back catalog of virtually free and very good medicine, against which any new medicine would have to compete. That reduces the value of as-yet-undiscovered drugs. It also pushes drug R&amp;D towards the areas where we don’t have a catalog of good cheap stuff; areas where R&amp;D has generated less over the last 70 years, and so is likely to be harder.</p> <p>People also inevitably appropriated Eroom’s Law to justify what they wanted to do anyway. It reminds me of a line from a famous British TV comedy, <em>Yes, Prime Minister</em>, which is about a hapless politician who is ruthlessly managed by his civil servants: “Something must be done. This is something. Therefore, we must do it.” I do occasionally see papers that make the same kind of argument.</p> <p>Although a few people in the drug industry have told me that the paper became required reading, and while I see the Eroom graph in a lot of presentations, it’s not clear to me that anything different was done after the paper was read.</p> <div class="footnotes"> <ol> <li id="fn5"> <p><em>Drug innovation—what's slowing it down?</em>, Fred Steward and George Wibberley, Nature, 1980 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1038/284118a0">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r5" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2 class="title"><a id="s3">Decline</a></h2> <h3 class="head">Pay&nbsp;more.<br>Get&nbsp;less.</h3> </div> <p class="qst" id="q4">R&amp;D spending grew for decades, even as Pharma companies lost money on their investments. How did competition factor in? At what point does R&amp;D spending turn into a race to outspend everyone else?<a class="qst-lnk" href="#q4"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Returns on R&amp;D are very stochastic. The industry makes an enormous amount of its profits from a very small number of drugs, so if you think you might have one of those drugs, then you expect your returns on R&amp;D to be relatively high.</p> <p>Even for the big companies, the economics are very sensitive to one or two products, and so long as a few people in the industry are winning, it’s very hard for other people to walk away from the game.</p> <p>As a result, the industry could generate poor returns for relatively long periods of time, and few drug companies would be willing to take the painful measures they would otherwise apply if they were narrowly maximizing shareholder value.</p> <p>R&amp;D spending as a percentage of sales is at an all-time high. For the big firms, it is 15-20 percent of sales versus roughly 5 percent of sales in the “golden age” of drug discovery in the 1960s. The financial returns on R&amp;D investment look to be at an all-time low.</p> <p>There’s an element of the agency problem at work here. Few people who fight their way to the top of a drug company do so because they want to fire all the scientists and pay a bigger dividend. Typically, what they really want is to discover more profitable drugs.</p> <p>As long as some companies in the industry seem to be doing well, firms can plausibly express confidence in their pipeline and scientists, and defend their use of shareholders money, despite the fact that, on average, they’re going to lose some of it.</p> <p>Finally, in the last decade, the debacle with a company called Valeant made R&amp;D cost-cutting less fashionable. Valeant was transparent in its opinion that the drug industry’s returns on R&amp;D were lousy, so it borrowed money to acquire a slew of other drug companies, and slashed their R&amp;D spending.</p> <p>At the same time, and away from the spotlight, Valeant was ruthless in ramping up the prices of the drugs of the companies it acquired. It was also quietly buying up pharmacy companies to make it easier to force insurance companies to cough up the cash for the drugs whose prices it had inflated.</p> <p>Valeant looked untouchable until things started to unravel in 2014–2015. The company’s behavior invited scrutiny from a few short sellers and journalists, and then from U.S. politicians. Pricing came under scrutiny, the growth evaporated, the company was left with too much debt, and the stock price <span class="txt-wrap">cratered.<sup><a href="#fn6" id="r6" class="fn-btn fn-btn-top">6</a></sup></span></p> <p>So while the financial returns on R&amp;D may be poor, the idea that you slash R&amp;D costs in response has been discredited. No one wants to look like Valeant.</p> <p class="qst" id="q5">The standard list of fixes to raise drug R&amp;D productivity tend to focus on process efficiency and cost-cutting. Why haven’t these solutions been enough to stop and reverse Eroom’s law?<a class="qst-lnk" href="#q5"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Simply put, they’re addressing the wrong class of problems. Suppose we were looking at the oil industry, and we found that it cost a hundred times more to produce a barrel of oil today than it did in 1950, despite the fact that your technology for pumping oil out of the ground got billions of times cheaper.</p> <p>Under those circumstances, no one would say the primary problem that the oil industry has is that the reporting lines are wrong, and we need to fix the organizational structure and get the drill procurement processes sorted out. It would be obvious that there’s a geological explanation for the problem.</p> <p>When drug companies talk to their shareholders, I suspect they talk about processes and cost-cutting because that’s the sort of thing shareholders can understand. You talk less about the science and technology choices because that’s very hard to evaluate from the inside, let alone the outside.</p> <p>It’s very difficult to engage in those technical conversations, even for scientists. If you’re a cancer biologist in a drug company, it’s hard for you to assess respiratory medicine or depression. Expertise tends to be narrow.</p> <p>Even when company executives shrug their shoulders and give the default explanation, that it’s some kind of “low-hanging fruit” problem, that’s still not a very straightforward or easy conversation to have with shareholders.</p> <p>After all, the fruit ain’t gonna get any lower. If firms primarily blame the exhaustion of some set of technological opportunities, they’re almost telling their shareholders that they should be doing less R&amp;D.</p> <p class="qst" id="q6">In your 2012 paper, you anticipated that Eroom's law wouldn't continue to hold, and indeed, we've seen an uptick in the number of new drug approvals in the last decade. Has the industry turned a corner?<a class="qst-lnk" href="#q6"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>FDA approvals have almost doubled in the last decade. Where we were getting 20-25 drug approvals a year before 2010, we’re running 40-50 approvals a year at the moment.</p> <p>A very large proportion of those drugs have been for oncology and for rare diseases. These two categories have become attractive for a number of reasons:</p> <ol> <li>They are very price-insensitive markets, where the drug industry has discovered over time quite how much it can charge.</li> <li>The regulatory environment in those areas has been relatively benign.</li> <li>The target-based drug discovery that drug companies industrialized works better for genetically simple diseases, like orphan diseases and molecularly-defined cancer subtypes, where much of the pathology can be blamed on a single gene that you can isolate and characterize in the discovery process.</li> </ol> <p>These days, the industry likes to talk about “unmet medical needs,” which are often one of these therapy areas with small patient groups where good medicinal solutions are lacking.</p> <p>To a certain extent, this is a euphemistic way the industry found to talk about the drug R&amp;D productivity problem, as “unmet medical needs” is really the inverse of the low-hanging fruit problem.</p> <p>One could try to paint a quantitative picture of the areas where there is both unmet medical need and a tractable technological opportunity. I haven’t seen that sketched out, but I suspect that if one tried to sketch it out in detail, one might find it smaller than shareholders would hope.</p> <p>As a result, I doubt that the current uptick in drug approvals will have the public health impact of the great drugs discovered from the 1940s through the 1970s.</p> <div class="footnotes"> <ol> <li id="fn6"> <p><em>Valeant: A timeline of the big Pharma scandal</em>, Fortune, 2015 <a class="fn-ext-lnk" target="_blank" href="https://fortune.com/2015/10/31/valeant-scandal/">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r6" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2 class="title"><a id="s4">Discovery</a></h2> <h3 class="head">Find&nbsp;a&nbsp;better<br>role&nbsp;model.</h3> </div> <p class="qst" id="q7">You've compared modern drug discovery to a ship that can sail the ocean at great speed, but never reach the small island in the middle, because it's missing a compass. What do you think is holding back drug discovery today?<a class="qst-lnk" href="#q7"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>The rate-limiting step in drug R&amp;D has to do with what people in the drug industry call “target validation” and what I would call “screening and disease model validity.” Does your piece of biological machinery work as expected when you put your drug into a real person with the disease this machinery is meant to cure?</p> <p>You can only easily experiment on your biological machinery outside of humans, whether in a test tube, in a rat, or with a bit of tissue in a dish. And everyone in the drug industry knows that good models are better than bad models.</p> <p>Yet, until you run the decision-theoretic maths, which very few people have done, you don’t realize that a marginally better model is 10 or even 100 times more productive.</p> <p>British cycling has been very successful in recent years under Dave Brailsford, whose philosophy is that if you make enough incremental changes, they add up to a substantial improvement in aggregate.</p> <p>Likewise, if I’m right about the very strong quantitative relationship between small changes in model validity and R&amp;D productivity, then I actually think there’s a lot of small things that could be done by drug companies that would cumulatively have quite a big effect.</p> <p>It would also help if the drug industry realized that some therapeutic areas are currently unmodelable, and didn’t work on them until model quality improves.</p> <p>In addition, I strongly suspect that the world could invest a lot more in experimental medicine, where you try and shift the latest stages of the drug discovery process out of animals and into humans. Over the last couple of decades, this approach hasn’t been very fashionable, since it doesn’t fit well with genomic reductionism, but I think it may well be more predictive.</p> <p class="qst" id="q8">If marginal differences in model quality can be orders of magnitude more predictive, why hasn't the drug industry been investing in better target validation tools?<a class="qst-lnk" href="#q8"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>In the 1980s, chemistry was the difficult bit in drug R&amp;D and patents were great for protecting chemistry. Today, it’s getting the biological mechanisms to work that’s difficult, and it’s very hard for companies to appropriate and protect that value, because there isn’t such robust intellectual property protection around target validation.</p> <p>You could spend a $1 billion working out a biological mechanism, and then patent a drug against it, and the minute that drug shows success in early-stage trials, ten other companies can produce good chemistry against that target that won’t infringe your patents.</p> <p>If the public authorities were amenable to this, you could either have more public sector investment in screening and disease models, or you could change intellectual property rights in such a way as to shift the economic incentives for private companies.</p> <p class="qst" id="q9">It's not uncommon for people to discover unexpected uses for drugs in the real world. Biology is messy and it reuses stuff, as you put it, so can we rehabilitate trial-and-error testing in drug discovery?<a class="qst-lnk" href="#q9"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>There’s probably much less work on this than there should be, but a combination of medics and innovation economists in the U.S. have done a study looking at all of the FDA drug approvals in a particular year. When they traced all of the subsequent uses for those drugs, they found that up to half of all new respectable uses of those drugs were discovered in the field by physicians or patients unassociated with academic institutions or the drug industry.</p> <p>What’s remarkable about that is there are only about 1,400 approved drugs. Of course, that’s heavily enriched for stuff that we know isn’t toxic, and which has a biological effect, nonetheless that’s not an awful lot of compounds.</p> <p>The sample size in which these observations are being made is also very small. It’s typically in a single human, but that’s a highly valid model of a human who has a disease, and as a result, you get a much higher predictive value.</p> <p>Yet despite these facts, academic fashion, economic incentives, and intellectual property laws all work against field discovery.</p> <p>Present-day medicine is dominated by an approach called “Evidence-based medicine,” which holds phase III randomized control trials, and meta-analyses of those trials, to be true and believable in a way that nothing else is.</p> <p>However, phase III trials typically recruit patients who are unlike the patients who get the drugs in the real world, and the meta-analyses are based on the phase III trials the drug companies chose to run.</p> <p>In other words, randomized control trials lack ecological validity, even if they manage to avoid statistical bias, whereas observational studies do risk statistical bias, but they’re conducted in patient populations who are like the patients using the drug in the real world.</p> <p>Nonetheless, the evidence-based medicine movement is very strong, and it doesn’t like things like case reports or observational studies, and that tends to exclude field discovery from consideration.</p> <p>Then, from an economic standpoint, once a drug goes on the market, the patent expiry clock starts ticking, and that makes it very difficult to invest substantially in the kind of evidence that would back up the field discoveries.</p> <p>In principle, a world in which high-fidelity data on patient responses to pharmacology is systematically captured and analyzed could do great things for this kind of serendipitous, user-centric innovation. So in a sense, I think computers should point things in the right direction.</p> <hr class="hr-show"> </article> <div class="bottom-toc"> <a href="/research">Explore our research</a><div class="rg-aro blu-aro tp-aro po-aro r-aro"></div> </div> <div class="digest-form-wrapper"> <div class="digest-form-header"> <h2 class="title">Digest</h2> <h3 class="head">This one<br>&nbsp;&nbsp;is a keeper.</h3> <p class="deck">One email a month. Our latest research.</p> </div> <div id="mc_embed_signup"> <form action="https://refoundable.us4.list-manage.com/subscribe/post?u=6d6a968ed0a3a9cdca29ca559&amp;id=2fd5737891" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank" novalidate=""> <div id="mc_embed_signup_scroll"> <div class="mc-field-group"> <label for="mce-EMAIL">Get the digest</label> <input type="email" placeholder="alan.shepard@example.com" name="EMAIL" class="required email" id="mce-EMAIL"> </div> <div id="mce-responses" class="clear"> <div class="response" id="mce-error-response" style="display:none"></div> <div class="response" id="mce-success-response" style="display:none"></div> <div class="response" style="display:none"><a></a></div> </div> <div style="position:absolute;left:-5000px" aria-hidden="true"><input name="b_6d6a968ed0a3a9cdca29ca559_2fd5737891" tabindex="-1"></div> <div class="clear"><input type="submit" value="Subscribe instantly" name="subscribe" id="mc-embedded-subscribe" class="button"><div class="rg-aro blu-aro sh-aro po-aro r-aro"></div></div> </div> </form> <div style="display:none"><div class="mce_inline_error"></div></div> </div> <script type="text/javascript" src="//s3.amazonaws.com/downloads.mailchimp.com/js/mc-validate.js"></script><script type="text/javascript">jQuery,window.fnames=new Array,window.ftypes=new Array,fnames[0]="EMAIL",ftypes[0]="email";var $mcj=jQuery.noConflict(!0)</script> </div> <div style="display:none"><span class="essay-nav-scroll"></span><span class="essay-btn-scroll"></span></div> </main> <footer id="footer-main" class="footer footer-light"> <div class="return-top"><a href="#top"><div class="bo-aro tp-aro slv-aro u-aro"></div></a></div> <p>© 2019–<span id="current-year">2020</span> Refoundable LP</p> <ul> <li> <a href="/privacy">Privacy</a> </li> <li> <a href="/terms">Terms</a> </li> <li> <a href="/about#contact">Contact</a> </li> </ul> </footer> <script></script> <script>function stickyNav(){var e=document.getElementById("sticky-nav"),t=document.getElementsByClassName("sticky-btn");if(45<document.body.scrollTop||45<document.documentElement.scrollTop){e.classList.add("essay-nav-scroll");for(var s=0;s<t.length;s++)t[s].classList.add("essay-btn-scroll")}else for(e.classList.remove("essay-nav-scroll"),s=0;s<t.length;s++)t[s].classList.remove("essay-btn-scroll")}document.getElementById&&(onload=function(){setInterval("document.getElementById('current-year').firstChild.data = new Date().getFullYear()")})</script> <script>"serviceWorker"in navigator&&"refoundable.com"===window.location.hostname&&navigator.serviceWorker.register("/service-worker.js").then(function(e){console.log("ServiceWorker registration successful with scope: ",e.scope)}).catch(function(e){console.log("ServiceWorker registration failed: ",e)})</script> <script>!function(t,e){"function"==typeof define&&define.amd?define(function(){return e(t)}):"object"==typeof exports?module.exports=e:t.echo=e(t)}(this,function(u){"use strict";function d(t,e){if(function(t){return null===t.offsetParent}(t))return!1;var n=t.getBoundingClientRect();return n.right>=e.l&&n.bottom>=e.t&&n.left<=e.r&&n.top<=e.b}function c(){!i&&t||(clearTimeout(t),t=setTimeout(function(){s.render(),t=null},a))}var l,t,a,i,f,s={},h=function(){};return s.init=function(t){function e(t,e){return parseInt(t||e,10)}var n=(t=t||{}).offset||0,o=t.offsetVertical||n,r=t.offsetHorizontal||n;l={t:e(t.offsetTop,o),b:e(t.offsetBottom,o),l:e(t.offsetLeft,r),r:e(t.offsetRight,r)},a=e(t.throttle,250),i=!1!==t.debounce,f=!!t.unload,h=t.callback||h,s.render(),document.addEventListener?(u.addEventListener("scroll",c,!1),u.addEventListener("load",c,!1)):(u.attachEvent("onscroll",c),u.attachEvent("onload",c))},s.render=function(t){for(var e,n,o=(t||document).querySelectorAll("[data-echo], [data-echo-background]"),r=o.length,c={l:0-l.l,t:0-l.t,b:(u.innerHeight||document.documentElement.clientHeight)+l.b,r:(u.innerWidth||document.documentElement.clientWidth)+l.r},a=0;a<r;a++)n=o[a],d(n,c)?(f&&n.setAttribute("data-echo-placeholder",n.src),null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+n.getAttribute("data-echo-background")+")":n.src!==(e=n.getAttribute("data-echo"))&&(n.src=e),f||(n.removeAttribute("data-echo"),n.removeAttribute("data-echo-background")),h(n,"load")):f&&(e=n.getAttribute("data-echo-placeholder"))&&(null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+e+")":n.src=e,n.removeAttribute("data-echo-placeholder"),h(n,"unload"));r||s.detach()},s.detach=function(){document.removeEventListener?u.removeEventListener("scroll",c):u.detachEvent("onscroll",c),clearTimeout(t)},s})</script> <script>echo.init({offset:2500,throttle:250,unload:!1,callback:function(t,o){}})</script></body></html>